A cationic polymeric prodrug with chemotherapeutic self-sensibilization co-delivering MMP-9 shRNA plasmid for a combined therapy to nasopharyngeal carcinoma

Liu, Tao; Wu, Xidong; Chen, Shaohua; Wu, Peina; Han, Hong; Zhang, Hongbin; Li, Junzheng; Li, Guanxue; Zhang, Siyi

doi:10.1080/10717544.2019.1698674

Cited by 8 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, peptide nanofibers conjugated with siRNA or shRNA MMPs could effectively effective target MMPs ( Mazza et al, 2019 ). Another nanoplatform consisting of HPAA-MTX/shMMP-9 (cationic hyperbranched poly (amido amine) (HPAA) with MTX and shMMP-9 plasmid) could significantly reduce the tumor growth in MCF 7 tumor-bearing animal as well as the decrease in the invasiveness and apoptosis induction in nasopharyngeal carcinoma HNE-1 cells ( Tang et al, 2018 ; Liu et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review

Mustafa

Koran

AlOmair

2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that regulate the turnover of extracellular matrix (ECM) components. Gross and La Piere discovered MMPs in 1962 during an experiment on tissue samples from a tadpole’s tail. Several subtypes of MMPs have been identified, depending on their substrate specificity and localization. MMPs are involved as essential molecules in multiple and diverse physiological processes, such as reproduction, embryonic development, bone remodeling, tissue repair, and regulation of inflammatory processes. Its activity is controlled at various levels such as at transcription level, pro-peptide activation level and by the activity of a family of tissue inhibitors of metalloproteinase, endogenous inhibitors of MMPs. Cancer metastasis, which is the spread of a tumor to a distant site, is a complex process that is responsible for the majority of cancer-related death It is considered to be an indicator of cancer metastasis. During metastasis, the tumor cells have to invade the blood vessel and degrade the ECM to make a path to new loci in distant places. The degradation of blood vessels and ECM is mediated through the activity of MMPs. Hence, the MMP activity is critical to determining the metastatic potential of a cancer cell. Evasion of apoptosis is one of the hallmarks of cancer that are found to be correlated with the expression of MMPs. As a result, given the importance of MMPs in cancer, we describe the role of these multifunctional enzymes MMPs in various aspects of cancer formation and their rising possibilities as a novel therapeutic target in this review. There is also a brief discussion of various types of therapeutic components and drugs that function against MMPs.

show abstract

Section: Introductionmentioning

confidence: 99%

Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review

Mustafa

Koran

AlOmair

2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Meanwhile, the hyperbranched molecular structure and the degradation ability of HPG could also contribute to the increased compatibility of the β-CD-HPG-RGD NPs. 37 Therefore, these compatible NPs are suitable for drug delivery.…”

Section: Resultsmentioning

confidence: 99%

Functional drug carriers formed by RGD-modified β-CD-HPG for the delivery of docetaxel for targeted inhibition of nasopharyngeal carcinoma cells

Zhou

Wang

et al. 2022

RSC Adv.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, a similar nanoplatform was created with Tf conjugation ( Liu T. et al, 2019b ). This nanosystem consists on hyperbranched poly(aminoamide) (PAA), MTX, shMMP-9 plasmid and Tf (Tf-PAA-MTX/pMMP-9).…”

Section: Matrix Metalloproteinases’ Contribution To Cancer Diagnosis ...mentioning

confidence: 99%

Nanotechnology and Matrix Metalloproteinases in Cancer Diagnosis and Treatment

González-Ávila

Sommer²,

García-Hernández³

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Cancer is still one of the leading causes of death worldwide. This great mortality is due to its late diagnosis when the disease is already at advanced stages. Although the efforts made to develop more effective treatments, around 90% of cancer deaths are due to metastasis that confers a systemic character to the disease. Likewise, matrix metalloproteinases (MMPs) are endopeptidases that participate in all the events of the metastatic process. MMPs’ augmented concentrations and an increased enzymatic activity have been considered bad prognosis markers of the disease. Therefore, synthetic inhibitors have been created to block MMPs’ enzymatic activity. However, they have been ineffective in addition to causing considerable side effects. On the other hand, nanotechnology offers the opportunity to formulate therapeutic agents that can act directly on a target cell, avoiding side effects and improving the diagnosis, follow-up, and treatment of cancer. The goal of the present review is to discuss novel nanotechnological strategies in which MMPs are used with theranostic purposes and as therapeutic targets to control cancer progression.

show abstract

A cationic polymeric prodrug with chemotherapeutic self-sensibilization co-delivering MMP-9 shRNA plasmid for a combined therapy to nasopharyngeal carcinoma

Cited by 8 publications

References 32 publications

Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review

Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review

Functional drug carriers formed by RGD-modified β-CD-HPG for the delivery of docetaxel for targeted inhibition of nasopharyngeal carcinoma cells

Nanotechnology and Matrix Metalloproteinases in Cancer Diagnosis and Treatment

Contact Info

Product

Resources

About